2026-10-08
The FDA has an ongoing safety review of the abortion pill (mifepristone). The agency has said the review will not conclude until next year (March, per one report). Officials had previously pledged to study the drug's safety.
The two outlets frame the same delay in opposite directions based on whose expectations are being thwarted. CBS News frames the extended timeline as a setback for abortion rights opponents who wanted the drug restricted sooner, emphasizing their 'condemnation' of the delay. The Federalist frames the delay as evidence of the FDA dragging its feet on a promised safety review, emphasizing the long gap (over two years) since RFK Jr. and the former commissioner pledged action, implying the agency is slow-walking scrutiny of the drug.
Presents the delay as a setback specifically for abortion rights opponents who wanted stricter action sooner, framing the FDA's timeline as a continuation of standard review process.
The FDA says its ongoing safety review of the nation's main abortion pill will continue into next year, a timeline quickly condemned by abortion rights foes hoping to see the drug's use curtailed.
Framing analysis generated by claude-sonnet-5. It describes how coverage differs, not who is correct.